(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
...
Adaptive Biotechnologies (ADPT) said Wednesday it launched its new T-cell test for the early detection of Lyme disease in adult patients who show signs and...
Adaptive Biotechnologies (ADPT) has an average rating of outperform and price targets ranging from $7.50 to $25, according to analysts polled by Capital...
| Address | 1165 Eastlake Avenue East Seattle, Washington 98109 |
| Phone | +1.206.659.0067 |
| Number of Employees | 346 |
| Recent SEC Filing | 08/05/2022 4 |
| Chairman & Chief Executive Officer | Chad Robins |
| President | Julie Rubinstein |
| Chief Operating & Technical Officer | R. Mark Adams |
| Chief Financial Officer | Tycho W. Peterson |
| Price Open | $12.23 |
| Previous Close | $12.12 |
| 52 Week Range | $5.96 - 40.00 |
| Market Capitalization | $1.8 B |
| Shares Outstanding | 142.9 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 11/02/2022 |
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
| Price / Earnings | N/A |
| Earnings per Share | -$1.64 |
| Beta vs. S&P 500 | N/A |
| Revenue | $55.7 M |
| Net Profit Margin | -145.37% |
| Return on Equity | -39.90% |
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |
